Patient's Guide to Common Side Effects and Contraindications of Sunitinib (Sutent)

Sunitinib (Sunitinib) is an oral multi-target tyrosine kinase inhibitor, mainly used to treat diseases such as renal clear cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumors (pNET). By inhibiting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), VEGFR Through pan>c-KIT and RET signaling pathways, sunitinib can block tumor angiogenesis and inhibit tumor cell proliferation, thereby delaying tumor progression. However, as a targeted drug, sunitinib also has certain adverse reactions and contraindications during treatment, and patients need to strictly follow medical instructions.

Common side effects

The most common side effects of sunitinib include fatigue, decreased appetite, nausea, vomiting, diarrhea, and mouth ulcers. These symptoms are usually mild to moderate and can be relieved with dietary modifications, anti-nausea medications, or topical care. In terms of blood system, some patients may experience thrombocytopenia, leukopenia or anemia. It is recommended to regularly monitor blood routine during medication so that abnormalities can be detected and dealt with in a timely manner.

Skin reactions are also common adverse events with sunitinib treatment and include hand-foot syndrome, rash, and alopecia. Hand-foot syndrome manifests as redness, swelling, pain or desquamation of the palms and soles of the feet, which can be intervened by local moisturizing, reducing friction and adjusting dosage. Some patients may develop high blood pressure, accelerated heart rate, or impaired cardiac function. Therefore, blood pressure, electrocardiogram, and cardiac function indicators should be monitored regularly during treatment.

Contraindications and precautions

Sunitinib is contraindicated in patients with known hypersensitivity to its components, as well as in pregnant and breastfeeding women, as the drug may cause serious side effects in the fetus or infant. Use with caution or avoid use in patients with severe hepatic impairment, cardiac insufficiency, or recent severe bleeding. At the same time, patients with severe myelosuppression, severe infection, or significant gastrointestinal ulcers also need to be cautious.

While using sunitinib, patients should strictly abide by the doctor's instructions, take the medicine on time, and should not increase or decrease the dose on their own. If serious side effects occur, contact your doctor immediately and suspend or adjust the dose if necessary. In addition, patients should pay attention to interactions with other drugs. For example, some antifungals, antibiotics or anticoagulants may affect the blood concentration of sunitinib and increase the risk of side effects. Therefore, you should inform your doctor about all the drugs you are taking before taking them, and conduct regular liver function, kidney function and blood routine tests.

In summary, sunitinib, as a multi-target anti-tumor drug, can effectively delay tumor progression and improve patient prognosis in clinical practice. However, its side effects are diverse and may be serious. Patients need to closely monitor their physical condition during medication, regularly review hematology and cardiac function indicators, and strictly abide by contraindications and precautions. By scientifically managing side effects and rationally adjusting medication regimens, patients can maximize the therapeutic benefits of sunitinib and improve their quality of life and long-term prognosis while ensuring safety.

Reference materials:https://www.drugs.com/